Decoy Therapeutics Inc
NASDAQ:DCOY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Decoy Therapeutics Inc
NASDAQ:DCOY
|
US |
|
S
|
Sturm Ruger & Company Inc
F:ST2
|
US |
|
Binggrae Co Ltd
KRX:005180
|
KR |
|
Merdeka Copper Gold Tbk PT
F:B0C
|
ID |
|
Fission 3.0 Corp
XTSX:FUU
|
CA |
|
Carlyle Group Inc
NASDAQ:CG
|
US |
|
E
|
enGene Therapeutics Inc
NASDAQ:ENGN
|
CA |
|
Bank First Corp
NASDAQ:BFC
|
US |
|
C
|
Cancambria Energy Corp
XTSX:CCEC
|
CA |
|
DHT Holdings Inc
NYSE:DHT
|
BM |
Intrinsic Value
Is DCOY undervalued or overvalued?
See the intrinsic value estimate for
Decoy Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
DCOY looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with DCOY’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Decoy Therapeutics Does
Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 11 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
- Headquarters
- United States of America US
- Employees
- 11
- IPO date
- Jan 29, 2015
Revenue & Expenses Breakdown
Decoy Therapeutics Inc
Earnings Waterfall
Decoy Therapeutics Inc
The intrinsic value for
Decoy Therapeutics Inc (DCOY) under the Base Case is hidden USD.
Compared with the current market price of 1.03 USD, the stock appears hidden.